Determination of antibiotic resistance rates of Escherichia coli and Klebsiella pneumoniae isolates, which are the causative agents of urinary tract infection in pregnant women

Year 2023, , 97 - 101, 27.03.2023

Süheyla Aydoğmuş , Esra Kaya Kılıç

https://doi.org/10.38053/acmj.1240882

Abstract

Aim: Urinary tract infections are common infections during pregnancy. Infections seen during pregnancy have a spectrum ranging from asymptomatic bacteriuria to cystitis, pyelonephritis and, urosepsis. In this study, it was aimed to determine the antibiotic resistance rates of Escherichia coli (E. coli) and Klebsiella pneumoniae (K. pneumoniae) isolates isolated from urinary cultures of pregnant women who applied to the Ankara Training and Research Hospital.
Material and Method: The identification and antibiotic susceptibility of E. coli and K. pneumoniae isolates isolated from urinary samples of pregnant women who applied to the Ankara Training and Research Hospital between January 2021 and December 2022 were investigated with VITEK-2 (Biomerioux, France) fully automated system, and the presence of extended-spectrum beta-lactamase (ESBL) was investigated by combined disc diffusion method. The obtained data were analysed retrospectively.
Results: Bacterial growth was detected in 1090 (1.2%) out of a total of 8923 urine samples over a two-year period. 480 (4.4%) of the microbial agents reproducing in urine culture were E. coli and 105 (0.96%) were K. pneumoniae. The rate of extended-spectrum beta-lactamase (ESBL) in E. coli strains was 16.04% (77/480), and the rate of ESBL in K. pneumoniae strains was 20.9% (22/105). Resistance rates of amoxicillin-clavulanic acid, ceftriaxone, phosphomycin, ciprofloxacin, piperacillin-tazobactam, nitrofurantoin, imipenem, meropenem, ertapenem in ESBL negative E. coli strains were 15.9%, 8.82%, 20%, 11.1%, 5.88%, 0%, 0%, 0% and 0%, respectively. Resistance rates of amoxicillin-clavulanic acid, ceftriaxone, phosphomycin, ciprofloxacin, piperacillin-tazobactam, nitrofurantoin, imipenem, meropenem, ertapenem in ESBL positive E. coli strains were determined as 66.5%, 100%, 2.2%, 33.8%, 11.5%, 0%, 0%, 0% and, 0%, respectively. Resistance rates of amoxicillin-clavulanic acid, ceftriaxone, phosphomycin, ciprofloxacin, piperacillin-tazobactam, nitrofurantoin, imipenem, meropenem, ertapenem in ESBL negative K. pneumoniae strains were 53%, 100%, 12.5%, 28.5%, 2.2%, 3.5%, 0%, 0% and, 4.5%, respectively. Resistance rates of amoxicillin-clavulanic acid, ceftriaxone, phosphomycin, nitrofurantoin, ciprofloxacin, piperacillin-tazobactam, imipenem, meropenem, ertapenem in ESBL positive K. pneumoniae strains were 62.5%, 100%, 12.5%, 35%, 28.5%, 22.7%, 0%, 0% and, 4.5%, respectively.
Conclusion: According to the antibiotic susceptibility data in our hospital, phosphomycin or carbapenems may be preferred due to the low resistance rate in the empirical treatment of E. coli-related urinary tract infections in pregnant women. In the treatment of urinary tract infections due to K. pneumoniae, phosphomycin, piperacillin-tazobactam or carbapenems may be preferred due to low resistance rates.

Keywords

Pregnancy, urinary tract infection, Escherichia coli, Klebsiella pneumoniae, extended-spectrum beta-lactamase, antibiotic susceptibility

References

• Sobel JD, Brown P. Urinary tract infections. In: Bennet JE, Dolin R, Blaser MJ, editors. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases 9th edi. 2020. p. 962-989 e4.
• Aşgın N, Eroğlu S, Çakmaklıoğulları EK. Gebelikte üriner sistem infeksiyonlarının ampirik tedavisinde hangi antibiyotikler ilk seçenek olmalıdır? ANKEM Derg 2018; 32: 94-102
• İnci M, İnci M, Davarcı M. Gebelikte görülen üriner sistem enfeksiyonları ve tedavisi. Turk Urol Sem 2011; 2: 124-6.
• Tandogdu Z, Wagenlehner FM. Global epidemiology of urinary tract infections. Curr Opin Infect Dis 2016;29: 73-9.
• Fasugba O, Gardner A, Mitchell BG, Mnatzaganian G. Ciprofloxacin resistance in community- and hospital-acquired Escherichia coli urinary tract infections: a systematic review and meta-analysis of observational studies. BMC Infect Dis 2015; 15: 545.
• Mancini A, Pucciarelli S, Lombardi FE, Barocci S, Pauri P, Lodolini S. Differences between community- and hospital-acquired urinary tract infections in a tertiary care hospital. New Microbiol 2020; 43: 17-21.
• Lee DS, Lee SJ, Choe HS. Community-acquired urinary tract ınfection by Escherichia coli in the era of antibiotic resistance. Biomed Res Int 2018; 2018: 7656752.
• Lee AC, Mullany LC, Koffi AK, et al. Urinary tract infections in pregnancy in a rural population of Bangladesh: population-based prevalence, risk factors, etiology, and antibiotic resistance. BMC Pregnancy Childbirth 2019; 20: 1.
• Rosana Y, Ocviyanti D, Halim M, et al. Urinary tract ınfections among Indonesian pregnant women and ıts susceptibility pattern. Infect Dis Obstet Gynecol 2020; 2020: 9681632.
• Ghouri F, Hollywood A, Ryan K. Urinary tract infections and antibiotic use in pregnancy - qualitative analysis of online forum content. BMC Pregnancy Childbirth 2019; 19: 289.
• Genç S, Dündar D. Escherichia coli ve Klebsiella pneumoniae suşlarında GSBL üretiminin saptanmasında VITEK- 2 otomatize sistemi ile çift disk sinerji testinin karşılaştırılması. Türk Mikrobiyol Cem Derg 2015; 45: 36-40.
• Gülay Z. Antibiyotiklere direnç mekanizmaları ve çözüm önerileri: beta-laktamlara ve karbapenemlere direnç. Hastane Infeks Derg 2001; 5: 210-29.
• European Committee on Antimicrobial Susceptibility Testing (EUCAST). EUCAST Clinical Breakpoint Table Version 10.0, Valid From 2020-01-01. Basel: EUCAST, 2020. http://www.eucast. org/clinical_breakpoints
• Luu T, Albarillo FS. Asymptomatic bacteriuria: prevalence, diagnosis, management, and current antimicrobial stewardship ımplementations. Am J Med 2022; 135: 236-44.
• Matuszkiewicz-Rowińska J, Małyszko J, Wieliczko M. Urinary tract infections in pregnancy: old and new unresolved diagnostic and therapeutic problems. Arch Med Sci 2015; 11: 67–77.
• de Rossi P, Cimerman S, Truzzi JC, et al. Joint report of SBI (Brazilian Society of Infectious Diseases), FEBRASGO (Brazilian Federation of Gynecology and Obstetrics Associations), SBU (Brazilian Society of Urology) and SBPC/ML (Brazilian Society of Clinical Pathology/Laboratory Medicine): recommendations for the clinical management of lower urinary tract infections in pregnant and non-pregnant women. Braz J Infect Dis 2020; 24: 110-9.
• Gupta K, Hooton TM, Naber KG, et al. Infectious Diseases Society of America; European Society for Microbiology and Infectious Diseases. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 2011; 52: 103-20.
• Gur D, Hascelik G, Aydin N, et al. Antimicrobial resistance in gram-negative hospital isolates: results of the Turkish HITIT-2 Surveillance Study of 2007. J Chemother 2009; 21: 383-9.
• Keskin BH, Çalışkan E, Kaya S, Köse E, Şahin İ. Üriner sistem enfeksiyonlarında etken bakteriler ve antibiyotik direnç oranları. Turk Mikrobiyol Cemiy Derg 2021; 51: 254-62.
• Duran H, Çeken N, Kula Atik T. İdrar kültüründen izole edilen Escherichia coli ve Klebsiella pneumoniae suşlarının antibiyotik direnç oranları: Dört yıllık analiz. Ankem Derg 2020; 34: 41-7.
• Avcıoğlu F, Behçet M. üriner sistem enfeksiyonu etkeni Escherichia coli izolatlarının çeşitli antibiyotiklere direnç oranlarının değerlendirilmesi. Turk Mikrobiyol Cemiy Derg 2020; 50: 172-7.
• Bayram Y, Eren H, Berktas M. İdrar örneklerinden izole edilen bakteriyel patojenlerin dağılımı ve GSBL pozitif ve negatif Escherichia coli suşlarının fosfomisin ve diğer antimikrobiyallere duyarlılık paterni. Ankem Derg 2012; 25: 232-36.
• Tekin A, Deveci Ö, Dal T, et al. Üropatojen Escherichia coli izolatlarına fosfomisin ve bazı antibiyotiklerin in vitro etkinliği. Ankem Derg 2012; 26: 61-8.